INVA moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 64%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on INVA as a result. In 41 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for INVA just turned positive on October 07, 2026. Looking at past instances where INVA's MACD turned positive, the stock continued to rise in 28 of 44 cases over the following month. The odds of a continued upward trend are 64%.
The 10-day moving average for INVA crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 57%.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where INVA advanced for three days, in 187 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
INVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 111 of 204 cases where INVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 55 cases where INVA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. INVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.234) is normal, around the industry mean (2.973). P/E Ratio (4.089) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (3.173) is also within normal values, averaging (9.059). Dividend Yield (0.047) settles around the average of (128.121) among similar stocks. P/S Ratio (4.092) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
KNSA moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend. In 26 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on KNSA as a result. In 71 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for KNSA just turned positive on October 07, 2026. Looking at past instances where KNSA's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Following a +5.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in 232 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The 10-day RSI Indicator for KNSA moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 36 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 67 cases where KNSA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
KNSA broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KNSA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.636) is normal, around the industry mean (10.407). P/E Ratio (76.217) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
INVA | KNSA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 66 | 2 | |
SMR RATING 1..100 | 28 | 59 | |
PRICE GROWTH RATING 1..100 | 55 | 35 | |
P/E GROWTH RATING 1..100 | 96 | 96 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KNSA's Valuation (79) in the Pharmaceuticals Major industry is in the same range as INVA (84) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew similarly to INVA’s over the last 12 months.
KNSA's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is somewhat better than the same rating for INVA (66) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew somewhat faster than INVA’s over the last 12 months.
INVA's SMR Rating (28) in the Pharmaceuticals Other industry is in the same range as KNSA (59) in the Pharmaceuticals Major industry. This means that INVA’s stock grew similarly to KNSA’s over the last 12 months.
KNSA's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as INVA (55) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew similarly to INVA’s over the last 12 months.
KNSA's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as INVA (96) in the Pharmaceuticals Other industry. This means that KNSA’s stock grew similarly to INVA’s over the last 12 months.
| INVA | KNSA | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 64% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 55% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 59% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 80% |
| Advances ODDS (%) | 3 days ago 63% | 3 days ago 76% |
| Declines ODDS (%) | 7 days ago 64% | 10 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 64% | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 54% | 1 day ago 68% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INVA’s FA Score shows that 1 FA rating(s) are green while KNSA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INVA’s TA Score shows that 7 TA indicator(s) are bullish while KNSA’s TA Score has 5 bullish TA indicator(s).
INVA (@Biotechnology) experienced а +0.96% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +1.09% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
INVA is expected to report earnings on Nov 04, 2026.
KNSA is expected to report earnings on Oct 27, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.
| Ticker / NAME | Correlation To KNSA | 1D Price Change % | ||
|---|---|---|---|---|
| KNSA | 100% | +1.37% | ||
| COYA - KNSA | 42% Loosely correlated | N/A | ||
| ABVC - KNSA | 40% Loosely correlated | +4.00% | ||
| JBIO - KNSA | 37% Loosely correlated | -1.45% | ||
| AMRN - KNSA | 36% Loosely correlated | +0.78% | ||
| SNDX - KNSA | 35% Loosely correlated | +3.19% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FDL | 53.34 | 1.46 | +2.81% |
| First Trust Morningstar Dividend Leaders Index Fund (FDL) | |||
| KAT | 59.67 | 0.17 | +0.28% |
| Scharf ETF (KAT) | |||
| BAIV | 28.63 | 0.04 | +0.12% |
| Brown Advisory International Value Select ETF (BAIV) | |||
| COAL | 23.82 | -0.16 | -0.67% |
| Range Global Coal Index ETF (COAL) | |||
| ACTS | 24.46 | -0.81 | -3.21% |
| FIS Tactical Equity ETF (ACTS) | |||